CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oncosil Medical Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oncosil Medical Ltd
Suite 503, Level 5, 15 Blue Street
Phone: +61 292233344p:+61 292233344 NORTH SYDNEY, NSW  2060  Australia Ticker: OSLOSL

Business Summary
OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient’s pancreatic tumors through an endoscopic ultrasound. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous-32 microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board DouglasCubbin 8/31/2023 8/7/2023
Chief Executive Officer, Managing Director, Executive Director NigelLange 1/21/2021 1/21/2021
Chief Financial Officer, Company Secretary Christian D.Cin 6/1/2023 6/1/2023
Non-Executive Director GabrielLiberatore 7/16/2023 7/16/2023

Business Names
Business Name
NDIS
NeuroDiscovery Ltd
OSL

General Information
Number of Employees: 2 (As of 6/30/2005)
Outstanding Shares: 3,103,954,978 (As of 3/27/2024)
Shareholders: 4,708
Stock Exchange: ASX
Fax Number: +61 292218535


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024